Ketotifen Fumarate

CHEMBL1633 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
425.5 g/mol
LogP
Phase
4

The fumarate salt form of ketotifen, used as an antihistamine and mast cell stabilizer for allergy and asthma prevention. It shares the same dual mechanism as the parent compound, blocking histamine and stabilizing mast cells.

Peso Molecular

425,5000 g/mol

TPSA

123,00 Ų

Áreas Terapêuticas

Mecanismo de Ação

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O

InChI

InChI=1S/C19H19NOS.C4H4O4/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19;5-3(6)1-2-4(7)8/h2-5,8,11H,6-7,9-10,12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

Molecular Formula

C23H23NO5S

HBD / HBA

2 / 7

Ligações Rotacionáveis

2

Átomos Pesados

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The fumarate salt form of ketotifen, used as an antihistamine and mast cell stabilizer for allergy and asthma prevention. It shares the same dual mechanism as the parent compound, blocking histamine and stabilizing mast cells.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Ketotifen Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1633. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5282408. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.